Aging-US published a Special Collection on Eye Disease which included "PU-91 drug rescues human age-related macular degeneration RPE cells; implications for AMD therapeutics" which reported that the PU-91 drug upregulates PGC-1α which is a critical regulator of mitochondrial biogenesis.

Since mitochondrial dysfunction is implicated in the pathogenesis of AMD, this study is based on the premise that repurposing of PU 91 might rescue AMD RPE cells from AMD mitochondria-induced damage. The authors report significant improvement in cell survival, mitochondrial health, and antioxidant potential following treatment with PU 91.

Dr. M. Cristina Kenney from The University of California Irvine said, "The incidence of Age-related Macular Degeneration (AMD) is increasing at an alarming rate in elderly population in the United States."

The incidence of Age-related Macular Degeneration (AMD) is increasing at an alarming rate in elderly population in the United States. Most AMD cases occur among Caucasian Americans, followed by Hispanic and other populations. Despite intensive study, a limited number of FDA-approved treatment options are available for treatment of AMD.

National Eye Institute projection, the estimated number of AMD patients is expected to rise to 5.44 million by 2050. PU-91 is a pro-drug that when metabolized is PPARα ligand and which was developed for the treatment of dyslipidemia.

The drug is estimated to have seen >5 million-years of patient exposure and remains an effective agent for certain dyslipidemias. These findings demonstrated that PU-91 preserved AMD mitochondrial function and integrity, and protected AMD RPE cybrids against oxidative stress-induced and mtDNA-induced apoptotic cell death.

The Kenney Research Team concluded in their Aging-US Research Output, "PU-91 rescues AMD RPE cybrids, and potentially could be repurposed as an FDA-approved drug to prevent/treat AMD. Since it improves mitochondrial function and has already been FDA-approved, the candidate therapeutic PU-91 will be an excellent treatmentoption for AMD. Repositioning of PU-91 will be a smoother transition from lab bench to clinic since the pharmacological profiles of PU-91 have been examined already. Furthermore, because of its extensive safety record it could be potentially prosecuted through NDA more rapidly than a drug-like new chemical entity. Bringing a disease modifying therapeutic to market for the most prevalent form of blindness, AMD, has substantial potential benefit for our aging populations world-wide."

Full Text - https://www.aging-us.com/article/102179/text

Correspondence to: M. Cristina Kenney email: [email protected]

Keywords: age-related macular degeneration (AMD), RPE, PGC-1α, RPE, mitochondria, FDA-approved drugs

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research as well as topics beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, cancer, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR among others), and approaches to modulating these signaling pathways.

To learn more about Aging-US, please visit http://www.Aging-US.com or connect with @AgingJrnl

Aging-US is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact

18009220957x105